Abstract
Ataxia telangiectasia is a monogenetic disorder caused by mutations in the ATM gene. Its encoded protein kinase ATM plays a fundamental role in DNA repair of double strand breaks (DSBs). Impaired function of this kinase leads to a multisystemic disorder including immunodeficiency, progressive cerebellar degeneration, radiation sensitivity, dilated blood vessels, premature aging and a predisposition to cancer. Since allogenic hematopoietic stem cell (HSC) transplantation improved disease outcome, gene therapy based on autologous HSCs is an alternative promising concept. However, due to the large cDNA of ATM (9.2 kb), efficient packaging of retroviral particles and sufficient transduction of HSCs remains challenging.
We generated lentiviral, gammaretroviral and foamy viral vectors with a GFP.F2A.Atm fusion or a GFP transgene and systematically compared transduction efficiencies. Vector titers dropped with increasing transgene size, but despite their described limited packaging capacity, we were able to produce lentiviral and gammaretroviral particles. The reduction in titers could not be explained by impaired packaging of the viral genomes, but the main differences occurred after transduction. Finally, after transduction of Atm-deficient (ATM-KO) murine fibroblasts with the lentiviral vector expressing Atm, we could show the expression of ATM protein which phosphorylated its downstream substrates (pKap1 and p-p53).
Similar content being viewed by others
Introduction
Ataxia Telangiectasia (A-T, OMIM #208900) is a rare multi-organ, monogenetic, autosomal recessive disorder with an incidence of 1 in 40,000–100,000 life births1, caused by mutations in the ataxia telangiectasia mutated (ATM) gene2. ATM is located at 11q22.33, with an open reading frame of 9,168 bp and a corresponding protein kinase ATM of 350 kDa2,4. ATM plays a major role in DNA damage response, coordinates DNA repair, cell cycle arrest, apoptosis and genome stability5,6,7,8. Upon induction of double strand breaks (DSB) by e.g. radiation or oxidative stress, ATM is activated through autophosphorylation, leading to the dissociation of the inactive dimer and the activation of its kinase activity. Following this, ATM phosphorylates multiple downstream substrates (more than 700 protein targets identified9). In A-T, the activation of ATM and the downstream signaling cascades are disrupted or impaired, leading to a great variety of symptoms10,11,12. Progressive cerebellar degeneration resulting in ataxia, telangiectasia (dilated blood vessels), immunodeficiencies (impaired B- and T-cell development) following recurrent sinopulmonary infections and lung damage, radiation sensitivity, endocrine abnormalities premature aging, and a predisposition to cancer are the most prominent clinical signs3,13,14. Life expectancy is severely compromised, mainly due to chronic pulmonary diseases and malignancies15. The first symptoms are normally recognized in young children (2–3 years) and most patients are wheelchair bound in their second decade of life1. A retrospective cohort study of 240 A-T patients in France showed a 20-year survival rate of 53.4%3. Until today, there is no curative therapy for A-T patients. Most therapy options are symptomatic and supportive as immunoglobulin replacement, antioxidant therapy or glucocorticoid administration to treat the neurological symptoms8. To overcome hematologic abnormalities, allogenic hematopoietic stem cell (HSC) transplantation is an option to treat A-T patients that has been recently successfully explored8,16. Preclinical mouse models give further evidence of beneficial effects of HSC transplantation8,17. Autologous HSC gene therapy, using retroviral vectors, may be an alternative attractive option to allogeneic HSC transplantations, as no matching donor is needed and the risk of graft versus host disease is avoided. For this, retroviral vectors can be used for ex vivo transduction of autologous hematopoietic stem and progenitor cells (HSPC) and their transplantation back into the patient. The stable integration into the genome of HSPC guarantees the lifelong genetic modification of all blood cells18.
Due to its large size, ATM gene transfer using retroviral vectors is challenging. Foamy viral vectors are derived from retroviruses of the spumaretrovirinae subfamily which have the largest retroviral genome. They are therefore the most promising retroviral platform to deliver large coding sequences and were shown to be able to transfer about 12 kb19,20. Foamy viral vectors show a broad host and cell-type tropism and can efficiently transduce slowly cycling cells since foamy viral genomes can persist in transduced cells until they undergo mitosis19,21. Foamy viral vectors have an integration preference close to transcription start sites22,23 but with lower frequency than gammaretroviral vectors, and they show less read through transcripts24 than other retroviral vectors, suggesting a probably safer vector profile. As a drawback for gene therapy applications, foamy viruses cannot naturally be pseudo-typed with others than its foamy viral envelopes because of the important foamy viral Gag-Env interaction during particle formation25. But, with specifically engineered Gag variants pseudo-typing of foamy viral vectors with for example the well-known VSV-G (Vesicular stomatitis virus G protein) envelope becomes possible. This however lowers titers of these vectors, as compared to foamy viral vectors with their own envelopes26, and therefore we did not chose to use this system in this work.
Vectors derived from gammaretroviruses were the first vectors to be successfully employed in hematopoietic stem cell gene therapy. However, the first generation of gammaretroviral vectors contained the viral enhancer/promoter sequences in their long terminal repeats (LTRs). In combination with the gammaretroviral preference to integrate in promoter regions of active genes and close to CpG islands23,27,28, the insertional activation of cellular genes, including proto-oncogenes, induced leukemias in some of the patients treated in early clinical trials29,30,31. By implementing the self-inactivating (SIN) configuration and the use of cellular rather than viral promoters, the safety of gammaretroviral vectors could majorly be improved32,33. Gammaretroviral vectors have a packaging capacity of up to 10 kb34, while HIV-derived lentiviral vectors are described to be able to incorporate sequences with 8–10 kb35,36. It was also shown that lentiviral vectors can transfer gene cassettes of up to 12 kb, but with a strong negative impact on viral titers with increasing transgene size37. In contrast to gammaretroviral vectors, lentiviral vectors can efficiently transduce non-dividing cells, making them suitable for the transduction of HSCs. Lentiviral vectors are known to preferentially integrate within active transcription units28,38 but due to the use of cellular promoters in the SIN lentiviral vectors, they have much less potential to induce insertional oncogenesis28,38,39 and are nowadays the most often used vectors in clinical trials for monogenetic hematopoietic diseases40,41,42. Lentiviral and gammaretroviral vectors can be pseudo-typed with heterologous envelopes to broaden cell tropism (e.g. VSV-G)27,34,43.
In our study, to develop a gene transfer tool for ATM, we compared the three retroviral vector platforms for their potential to efficiently transfer and express ATM.
Results
Foamy viral vectors for gene transfer of Atm
We generated a self-inactivating foamy viral vector for Atm gene transfer by inserting a codon-optimized murine Atm cDNA into the foamy viral vector backbone44,45 under control of an internal spleen focus forming virus (SFFV) promoter. For detection of transgene by flow cytometry, GFP (green fluorescent protein) was co-expressed in the 5’ position, using a F2A protease cleavage site (consecutively named Atm vectors, Fig. 1a). As foamy viral vectors cannot be naturally pseudo-typed with VSV-G without gag-env modification to enable interaction, we first compared different foamy viral envelopes derived from the human prototype foamy virus or the macaque simian foamy virus using a GFP-coding control vector (Supplementary Fig. S1a). Furthermore, we optimized the transfection conditions to produce foamy viral vectors with high titers (Supplementary Fig. S1b).
Using the best conditions and envelope, foamy viral GFP vectors were then produced with titers of 1.7 × 105 TU/mL (transducing units / mL) determined by flow cytometry, while foamy viral Atm vectors achieved titers of only 2.5 × 103 TU/mL (Fig. 2a + b). After two additional concentrating steps, foamy viral Atm vectors achieved titers of up to 1.6 × 105 TU/mL (Fig. 2b). Expression levels (as measured by the mean fluorescence intensity, MFI) of GFP.2A.Atm were 17-fold lower compared to the GFP control vector (Fig. 2c). In addition, efficient transduction of target cells (Atm-deficient murine fibroblasts, ATM-KO) could not be achieved using foamy viral vectors (Fig. 2a).
Lentiviral and gammaretroviral vectors for the expression of ATM
As transduction of ATM-KO fibroblasts with the foamy viral Atm vector was not possible, we next asked whether Atm may be expressed from lentiviral or gammaretroviral vectors. Therefore, we generated lentiviral and gammaretroviral Atm vectors (Fig. 1b + c). As the packaging of lentiviral and gammaretroviral GFP vectors with the foamy viral envelope SEwt, that had shown the highest titers with the foamy viral GFP vector, was inefficient (Supplementary Fig. S2), we used VSV-G enveloped lentiviral and gammaretroviral vectors for our further studies. Lentiviral and gammaretroviral Atm vectors could only be produced with titers of 1.2 × 104 TU/mL, compared to 7.7 × 106 TU/mL and 1.2 × 107 TU/mL for the smaller lentiviral and gammaretroviral GFP vectors, respectively. After concentrating steps, titers of 5.3 × 105 TU/mL (lentiviral) and 2.5 × 105 TU/mL (gammaretroviral) were obtained for the Atm vectors (Fig. 3a). The MFI in cells transduced with these Atm vectors was lower than the one achieved with the smaller GFP vectors. In addition, the lentiviral and gammaretroviral Atm vectors showed significantly higher expression intensities than the foamy viral Atm vector (Fig. 3b + Supplementary Fig. S3 + S4).
Comparison of the three vector platforms
Since the gene transfer of the GFP.2A.Atm coding sequence with lentiviral and gammaretroviral vectors was unexpected due to their size, we systematically compared titers by flow cytometry and mean vector copy number (VCN) and the contribution of RNA containing particles in the vector preparations of the three vector platforms.
First, we compared small control vectors expressing only GFP. All three vector platforms produced 1–2 × 1010 particles/mL. The transducing titer measured by flow cytometry was 7.7 × 106 TU/mL for the lentiviral vector and 1.2 × 107 TU/mL for gammaretroviral vectors, but only 1.6 × 105 TU/mL for the foamy viral vector (Fig. 4a). Similar titers were calculated when determining the mean VCN in transduced cells indicating that the integrated viral genome copies were actively expressing the transgene (Fig. 4a). We further measured the amount of RNA containing particles by quantitative PCR and detected significantly more in the supernatants of the lentiviral vector (22-fold), gammaretroviral vector (58-fold) and foamy viral vector (sevenfold) than were detected to be transducing (determined by VCN, Fig. 4a + b). Comparing the three vector platforms confirmed that the foamy viral vector was most successful in producing viral genome containing particles that were productively transducing target cells while the gammaretroviral vector was the least effective. However, the overall reached titers were lowest with the foamy viral vectors.
Titers of the Atm vectors determined by flow cytometry were markedly reduced compared to GFP vectors (700- to 1000-fold for lentiviral and gammaretroviral vector, 70-fold for foamy viral vector; Fig. 4c + f), however, integrated genome copies were readily detectable. Titers determined by the VCN were fivefold (lentiviral vector) and sevenfold (foamy viral vector) reduced, compared to the genome vector titer of the GFP control vectors, but 120-fold reduced for the gammaretroviral Atm vector (Fig. 4c + g). The amount of RNA containing particles on the other hand was much higher than were productively transducing, ~ 900-fold (lentiviral vector), ~ 2700-fold (gammaretroviral vector) and ~ 46-fold (foamy viral vector) higher (Fig. 4d). Because of the large coding sequence in the Atm vectors, we quantified in addition the amount of RNA in the particles based on an amplicon in the 5’ sequence of Atm, which will also detect truncated RNA genomes. However, we did not detect any differences between the amounts of RNA containing particles (Fig. 4h).
Taken together, the foamy viral vector showed the smallest ratio between RNA-containing particles and VCN titer and was therefore most efficient in integrating viral genomes of large size into target cells, while the gammaretroviral vector was the least effective. However, against our expectation, lentiviral and gammaretroviral vectors were able to transfer the transgene cassette of 10.2 kb, whereby the lentiviral Atm vector gave the best titers of all tested vectors and, therefore, appeared the most suitable for Atm gene transfer.
Functional correction of ATM-deficiency by lentiviral Atm gene transfer
We next investigated the potential restoration of ATM function in ATM-KO fibroblasts. Cells were transduced with lentiviral Atm vectors with a multiplicity of infection (MOI) of 0.5 (titrated on HT1080 cells). Three days post transduction, ATM-KO fibroblasts were 74% GFP-positive and ATM expression was 50% of wild-type levels, as detected by Western blot 24 days post transduction (Fig. 5a + Supplementary Fig. S5a).
The functionality of ATM was verified by testing the phosphorylation of H2AX, a histone involved in the responses to DSBs in wild type, ATM-KO and transduced ATM-KO fibroblasts 30 min after irradiation (5 Gy). Transduced cells showed a γH2AX level similar to wild type cells with an increased level of mono-ubiquitinated γH2AX compared to the ATM-KO control (Fig. 5b + Supplementary Fig. S5b + c). Mono-ubiquitinated γH2AX is a marker which is more related to DSBs than γH2AX, since γH2AX can also appear during apoptosis or severe chromatin damage46. We could thus show functional restoration of ATM protein in ATM-KO fibroblasts after transduction with lentiviral Atm vector.
Clinically relevant lentiviral vector demonstrates correction of ATM deficiency
For comparison of the vector platforms, vectors containing the SFFV promoter were used. Since this promoter is known to be able to induce malignant transformation by insertional activation of proto-oncogenes in the context of gene therapy31,33,47, we generated lentiviral vectors expressing the codon-optimized (co) Atm sequence (LV.EFS.GFP.2A.Atm_co), or the wild-type (wt) Atm sequence (LV.EFS.GFP.2A.Atm_wt) from the internal elongation factor 1 alpha short (EFS) promoter (Fig. 1d). All three vectors could be produced with similar titers, determined by flow cytometry (Fig. 6a). Furthermore, the lentiviral vectors containing the EFS promoter showed a significantly lower expression intensity of GFP compared to the vector expressing from the SFFV promoter (Fig. 6b).
Lastly, ATM-KO fibroblasts were transduced with the lentiviral vector containing the wt GFP.2A.Atm sequence driven by an internal EFS promoter. Transduced ATM-KO fibroblasts (15–20% GFP-positive) showed increased ATM protein levels compared to the ATM-KO control (35% of wt level, on day 10 post transduction, Fig. 6c, d) and an increased phosphorylation level of downstream substrates, namely p-Kap1 and p-p53 (Fig. 6e–g) after irradiation. These results demonstrated correction of ATM deficiency with a clinically relevant vector.
Discussion
The aim of our study was to develop a retroviral gene transfer vector for the delivery of Atm. Because foamy viral vectors are known to be able to transfer large cDNAs, we initially chose this vector platform. Despite the previously reported superior ability of the foamy viral vector to transfer large virus genomes into target cells19,20, this platform was not suited due to low titers and inefficient transduction of ATM-KO fibroblasts. In contrast, the efficient gene transfer of the large GFP.2A.Atm coding sequence (10.2 kb) from the lentiviral and gammaretroviral vectors tested, was unexpected, especially in the light of previous reports that the packaging capacity of these vectors would be limited to 8-10 kb in case of lentiviral vectors and 10 kb in case of gammaretroviral vectors, respectively. This limit was described to be caused by either reduced incorporation of viral genomes into virions (RNA encapsidation)37 or by incomplete viral RNAs lacking the 3’ ends/LTRs, leading to incomplete reverse transcription48. In our hands, there was no detectable difference in the physical amounts of RNA-containing particles between the small GFP vectors and the Atm vectors, arguing against the idea of the presence of truncated viral genomes in viral particles. Furthermore, there was no difference in the amount of RNA-containing particles when comparing the calculation done after the qPCR amplifying a product in the 5’ Atm sequence or in the WPRE sequence. Our results are in line with the findings of Sweeney et al.49 demonstrating that the RNA content in lentiviral particles is not affected by transgene size.
The largest drop of titers for vectors with large transgene size was found when comparing RNA-containing particles and transducing particles. While in small vectors, 2–20% of RNA containing particles lead to productive integration (8.6% for lentiviral GFP vector, 2.4% for gammaretroviral GFP vector and 20.2% for foamy viral GFP vector), this was less than 0.32% for large vectors (0.002% for lentiviral Atm vector, 0.01% for gammaretroviral Atm vector and 0.32% for foamy viral Atm vector). Therefore, the main impact on functional vector titers happened after transduction in target cells although complete viral genomes appear to be packaged into particles. It is likely that either the step of reverse transcription could be hampered or the complete integration of the transgene into the genome.
In our hands, the best correlation between RNA containing particles and transducing titers was detected using the foamy viral vectors. However, the foamy virus has the unique characteristic to reverse transcribe it’s RNA during production of vector particles, i.e. in contrast to lentiviral and gammaretroviral vectors, reverse transcription is largely completed in virus producing cells and a prominent part of the functional genome in foamy viral particles is dsDNA19,50. It was shown that the contribution of viral genome DNA in foamy viral particles is between 6 and 20%51 and that this DNA is mainly contributing to productive transduction52. Translating this to our quantification, 15–50% of the foamy viral DNA genome containing particles led to integration in transduced cells. However, it has to be mentioned that we did not directly quantify the amount of DNA in foamy viral particles, our methodology only detected RNA in the particles.
When comparing titers determined by flow cytometry or by VCN qPCR, calculated titers were in the same range with both methods for the GFP transgene, independent of the vector system. For the Atm vectors, functional titers determined via flow cytometry were much lower compared to genomic titers determined by VCN qPCR. The lentiviral vector showed the largest difference between functional titer and the genomic titer (Fig. 4E) indicating that not all integrated vector genomes were active.
GFP expression levels of the Atm vectors (as determined by MFI) were significantly lower compared to the GFP vectors. This might be due to a) a longer time needed by a cell to translate a larger mRNA transcript (rate of translation elongation estimated with five amino acids per second53), meaning there may be simply less translated proteins coming from the GFP.2A.Atm transcripts; or b) a preferred translation of shorter mRNAs, as shown by Guo et al.54 in a computational model. In this study they concluded that translation initiation efficiency for short mRNAs is higher compared to longer transcripts which can be explained by economizing energy resources. The same is true for the transcription of genes, which is also an energy costly process. Castillo-Davis et al.55 showed that introns from highly expressed genes are significantly shorter that introns from genes expressed at a low level, suggesting that huge coding sequences introduced with retroviral vectors could be transcribed and translated with lower frequency compared to shorter genes. Lastly c), the stability of mRNAs and their half-lives in a cell can highly influence the expression of the related protein56,57.
Using lentiviral vectors containing the GFP.2A.Atm sequence, we could reconstitute ATM protein levels in ATM-KO fibroblasts (50% of wt level). Corrected cells showed an increase of phosphorylated H2AX after irradiation, demonstrating a functional reconstitution. For clinical translation, we designed lentiviral vectors containing an EFS promoter instead of the SFFV promoter and we demonstrated that ATM protein levels were restored to 35% of wt level and phosphorylation of downstream substrates (pKap1 and p-p53) was increased. Taken together, we developed a gene transfer tool for delivery of the large coding sequence of Atm, which proofed to be functional in restoring some aspects of ATM deficiency. Our study, therefore, paves the way for preclinical models to evaluate ex vivo HSC gene therapy for human patients suffering from A-T.
Materials and methods
Vector constructs
Gammaretroviral (SRS11.SF.GFP.pre)58 and lentiviral (pRRL.PPT.SF.GFP.pre)59 plasmids were kindly provided by A. Schambach, Hannover Medical School. The foamy viral vector (puc2MD9) was generated by D. Lindemann, TU Dresden44,45. The foamy viral transfer vector plasmid 2MD9.pre was generated by inserting the WPRE element (derived from the pSRS11.SF.GFP.pre vector) into the puc2MD9 vector. The WPRE element was inserted directly after the GFP transgene with the help of Gibson Assembly cloning. The transfer vector plasmids pRRL.PPT.SF.GFP.F2A.HA.Atm.pre, pSRS11.SF.eGFP.F2A.HA.Atm.pre and puc2MD9.SF.GFP.F2A.HA.Atm.pre were generated by standard cloning techniques. The vector plasmids contain the transgene sequence (GFP.F2A.HA.Atm, codon-optimized) between the AgeI and NotI or BsrgGI site. In addition, lentiviral vectors containing an internal EFS promoter, expressing either the codon-optimized sequence or the wild-type GFP.2A.Atm sequence were cloned. For the codon-optimized EFS vector, standard cloning techniques were used and the GFP.2A.Atm sequence were inserted into a lentiviral backbone containing an EFS promoter. For the cloning of the lentiviral Atm wild-type vector, Gibson Assembly was used to introduce the transgene sequence into the lentiviral backbone.
Cell lines
The human kidney cell line HEK293T and the human fibrosarcoma cell line HT1080 were cultured in Dulbecco’s modified Eagle medium (DMEM, Sigma Aldrich), supplemented with 10% heat-inactivated fetal calf serum (FCS, Biochrom) and 1% L-glutamine (Life Technologies). The fibroblasts isolated from ear and tail tissue from Atm-deficient (129S6/SvEvTac-Atmtm1Awb/J) and Atm-competent mice60 were cultured in DMEM, supplemented with 10% heat-inactivated FCS (Biochrom), 1% L-glutamine (Life Technologies), 1% penicillin/streptomycin (AppliChem), 1% non-essential amino acids (NEAA, Gibco) as well as 50 µM mercaptoethanol (Life Technologies). All cells were cultured in a 5% CO2 humidified atmosphere at 37 °C. The isolation of fibroblasts from ear and tail tissue from mice has been described previously61.
Generation of vector supernatants
5 × 106 HEK293T cells were seeded in 10 cm plates, one day prior to transfection. On day of transfection, medium of cells was changed and 1% penicillin/streptomycin as well as 25 µM chloroquine (Sigma Aldrich) was added.
Gammaretroviral- and lentiviral vector production
Cells were transiently transfected at 60–70% confluency by calcium-phosphate transfection method. In case of lentiviral vector production, cells were transfected with either 10 µg (for lentiviral GFP vector) or 22 µg (for lentiviral Atm vector) lentiviral transfer vector plasmid, respectively, 10 µg gag/pol helper plasmid (pCDNA3.GP.4xC)59,62, 1.5 µg VSV-G helper plasmid (pMD2.G)58,63 and 5 µg Rev helper plasmid (pRSV_REV)62 per 10-cm plate. For gammaretroviral vector production, 10 µg (for gammaretroviral GFP vector) or 22 µg (for gammaretroviral Atm vector) gammaretroviral transfer vector plasmid, respectively, 15 µg gag/pol helper plasmid (pcDNA3.MLVg/p) and 1.5 µg VSV-G helper plasmid (pMD2.G)58,63 were added per 10-cm plate. Retroviral supernatants were collected 24 h and 48 h after transfection.
Foamy viral vector production
For foamy viral vector production, HEK293T cells seeded in 10 cm dishes were transiently transfected at 60–70% confluency by PEI (polyethylenimine) transfection method. Cells were transfected with 10.4 µg (for foamy viral GFP vector) or 22 µg (for foamy viral Atm vector) foamy viral transfer vector plasmid, respectively, 5.2 µg gag helper plasmid (pcoPG4)45, 2.4 µg pol helper plasmid (pcoPP wt)64 and 0.8 µg envelope helper plasmid (pcoSE wt)65. Foamy viral supernatants were collected 48 h and 72 h after transfection.
Supernatants were filtered through 0.45 µm sterile syringe filters to remove remaining cells and frozen at -80 °C, supplemented with 20 mM HEPES.
In some cases (when indicated), viral supernatants of the Atm vectors were concentrated in two additional steps. For this, ~ 220 mL viral supernatant was spun down at 50.000 × g for 2 h at 4 °C. Viral particles were resuspended in a volume of 0.6–0.8 mL. In a last step, the viral particles were transferred to an Amicon 0.5 mL 100 K concentrator column (Merck) and volume was reduced via centrifugation to a final volume of 100–150 µL leading to a final concentration step of ~ 1500-fold. Supernatants were aliquoted when needed and frozen at −80 °C.
Viral vector titers were determined by transducing HT1080 cells in the presence of protamine sulfate (4 µg/mL, Sigma Aldrich). For GFP vectors, 3.5 × 104 HT1080 cells were plated into 12-well format and for Atm vectors 1 × 106 HT1080 cells were plated in 10-cm plates 6–8 h in advance. Serial dilutions of the viral supernatant were incubated with the target cells. The percentage of GFP-expressing cells was determined by flow cytometric (FC) analysis 72 h after transduction with the BD Cytolex and analyzed with the CytExpert software. For the calculation of viral titers, samples with > 1% and < 30% GFP-positive cells were used. All transduction experiments were performed at least three times. Particle numbers in vector stocks were determined by nanoparticle tracking analysis (Nanosight NS300, Malvern Panalytical).
Detection of the mean vector copy number (VCN) by PCR
VCN was determined on genomic DNA from HT1080 cells, which were isolated seven days post transduction using the NucleoSpin Tissue Kit (Macherey–Nagel, Düren, Germany). TaqMan real time PCRs were performed with the TaqMan Fast Advanced Master Mix (ThermoFisher), using specific primers and probes complementary to the WPRE element or the PTBP2 gene as housekeeping gene. VCN was calculated by normalization to the housekeeping gene and quantification by a plasmid standard. PCRs were run on the StepOnePlus Real-Time PCR System (Applied Biosystems, Waltham, MA, USA).
Quantification of RNA containing retroviral particles
For quantification of RNA containing particles 500µL non-concentrated viral supernatant was resuspended in 500µL Trizol. RNA was isolated using the Direct-zol RNA MicroPrep Kit (Zymo Research, Irvine, CA, USA) following the manufactures’ protocol and afterwards cleaned up by RNA clean and concentrator Kit (Zymo research) to remove DNA contamination. Afterwards, the isolated RNA was reverse transcribed using RevertAid H Minus Reverse Transcriptase (Thermo Fisher Scientific) following the manufacturers’ protocols. Quantification of the WPRE element was performed as described above (VCN PCR) by using the primers and a probe complementary to the WPRE element. RNA containing particles were quantified by a plasmid standard. For quantification of RNA containing particles in GFP.2A.Atm vectors, primers and a probe binding to the 5’Atm were used in addition.
Western blot
If applicable, cells were irradiated with a 137Cs-g ray source with 0.036 Gy/s (Gamma-irradiator OB29/4, STS GmbH, Braunschweig) and incubated for 30 min. Protein lysates from irradiated or non-irradiated cells were extracted using RIPA Lysis buffer (Abcam) together with a protease inhibitor cocktail (PIC, Carl Roth) and Phosphatase inhibitor cocktail (Roche) following sonication (sonicator: Bandelin GmbH).
In case of ATM, protein extracts (50 or 100 μg per lane, determined with Bradford Assay) were loaded onto a NuPAGE® Novex 3–8% Tris–Acetate Gel (Invitrogen), electrophoresed and electro-transferred onto a 0.45 µM PVDF membrane (Mini Trans-Blot® System, BioRad) following manufacturers’ recommendations for high molecular weight proteins. Membranes were blocked either with 5% non-fat milk in PBS/ 0.1% Tween20 or with 5% BSA in PBS/ 0.1% Tween20 for 1 h and incubated overnight with a primary antibody against ATM (1:1000, D2E2 Rabbit mAb, Cell Signaling, #2873). For detection of γH2AX, protein extracts (50 μg per lane, determined with Bradford Assay) were loaded onto a 12% Mini-PROTEAN® TGX™ Precast Gel (Bio-Rad), electrophoresed and electro-transferred onto a 0.2 µM PVDF membrane (Mini Trans-Blot® System, BioRad) following manufacturers’ recommendations. Membranes were blocked with 5% non-fat milk in PBS/ 0.1% Tween20 for 1 h and incubated overnight with a primary antibody against γH2AX (1:2500, pSer139 rabbit pAb, Novusbio, NB100-384). For the detection of pKap1 or p-p53, protein extracts (50 μg per lane, determined with a Bradford Assay) were loaded onto a 12% Mini-PROTEAN® TGX™ Precast Gel (Bio-Rad), electrophoresed and electro-transferred onto a 0.45 µM PVDF membrane (Mini Trans-Blot® System, BioRad) following manufacturers’ recommendations. Membranes were blocked with 5% BSA in PBS/ 0.1% Tween20 for 1 h and incubated overnight with a primary antibody against pKap1 (1:2500, Ser824; rabbit, monoclonal, BL-246-7B5, Bethyl Laboratries, A700-013) or p-p53 (1:2500, Ser15; rabbit, monoclonal, D4S1H, rodent specific, CellSignaling, #12,571). As loading controls, Vinculin (1:2000, W18245A, rat, monoclonal BioLegend, 938,402) or β-Tubulin (rabbit, polyclonal, CellSignaling, #2146) were used. Membranes were incubated with a secondary antibody (1:2000, HRP donkey anti-rabbit IgG (Polyclonal), BioLegend, 406,401, or 1:5000, HRP goat anti-rat IgG (Polyclonal), ThermoFisher, 31,470) for 1 h. After incubation with a substrate (Clarity Western ECL Substrate, Bio-Rad) chemiluminescence signal was recorded with an imaging system (ChemiDoc Imaging System, Bio-Rad) and analyzed with Fiji Software.
Statistical analysis
Graphing and statistical analyses were done using GraphPad Prism version 9.5.0 (Graphpad software). Data are presented as mean ± SD, unless stated otherwise. For statistical testing between the means of 2 points, the 2-tailed, unpaired Student’s t test with Welch correction (*p < 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001) was used. For comparison between two or more groups, we used 1-way analysis of variation (ANOVA) with Tukey’s comparison test (*p < 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001); ns = not significant. Statistical details can be found in the main figure legends as well as in the supplemental figure legends.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
References
Mavrou, A., Tsangaris, G. T., Roma, E. & Kolialexi, A. The ATM gene and ataxia telangiectasia. Anticancer Res. 28, 401–405 (2008).
Savitsky, K. et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science (New York, N.Y.) 268, 1749–1753; https://doi.org/10.1126/science.7792600 (1995).
Micol, R. et al. Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype. J. Allergy Clin. Immunol. 128, 382–9.e1; https://doi.org/10.1016/j.jaci.2011.03.052 (2011).
Uziel, T. et al. Genomic Organization of the ATM gene. Genomics 33, 317–320; https://doi.org/10.1006/geno.1996.0201 (1996).
McKinnon, P. J. ATM and the molecular pathogenesis of ataxia telangiectasia. Ann. Rev. Pathol. 7, 303–321; https://doi.org/10.1146/annurev-pathol-011811-132509 (2012).
Shiloh, Y. & Ziv, Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat. Rev. Mol. Cell Biol. 14, 197–210 (2013).
Blackford, A. N. & Jackson, S. P. ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. Mol. Cell 66, 801–817; https://doi.org/10.1016/j.molcel.2017.05.015 (2017).
Sabino Pinho de Oliveira, B., Putti, S., Naro, F. & Pellegrini, M. Bone marrow transplantation as therapy for ataxia-telangiectasia: A systematic review. Cancers 12; https://doi.org/10.3390/cancers12113207 (2020).
Wang, X. et al. Structure of the intact ATM/Tel1 kinase. Nat. Commun. 7, 11655; 10.1038/ncomms11655 (2016).
Carranza, D. et al. Reconstitution of the ataxia-telangiectasia cellular phenotype with lentiviral vectors. Front. Immunol. 9, 2703; https://doi.org/10.3389/fimmu.2018.02703 (2018).
Di Siena, S. et al. Atm reactivation reverses ataxia telangiectasia phenotypes in vivo. Cell Death Dis. 9, 314; https://doi.org/10.1038/s41419-018-0357-8 (2018).
Kitagawa, R. & Kastan, M. B. The ATM-dependent DNA damage signaling pathway. Cold Spring Harbor Symposia Quant. Biol. 70, 99–109; https://doi.org/10.1101/sqb.2005.70.002 (2005).
Rothblum-Oviatt, C. et al. Ataxia telangiectasia: a review. Orphanet J. Rare Dis. 11, 159; https://doi.org/10.1186/s13023-016-0543-7 (2016).
Savitsky, K. et al. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Human Mol. Gene. 4, 2025–2032; https://doi.org/10.1093/hmg/4.11.2025 (1995).
Amirifar, P., Ranjouri, M. R., Yazdani, R., Abolhassani, H. & Aghamohammadi, A. Ataxia-telangiectasia: A review of clinical features and molecular pathology. Pediatric Allergy Immunol.: Off. Pub. Eur. Soc. Pediatric Allergy Immunol. 30, 277–288; https://doi.org/10.1111/pai.13020 (2019).
Bakhtiar, S. et al. Pre-emptive Allogeneic Hematopoietic Stem Cell Transplantation in Ataxia Telangiectasia. Front. Immunol. 9, 2495; https://doi.org/10.3389/fimmu.2018.02495 (2018).
Duecker, R. et al. Hematopoietic Stem Cell Transplantation Restores Naïve T-Cell Populations in Atm-Deficient Mice and in Preemptively Treated Patients With Ataxia-Telangiectasia. Front. Immunol. 10, 2785; https://doi.org/10.3389/fimmu.2019.02785 (2019).
Naldini, L. Gene therapy returns to centre stage. Nature 526, 351–360; https://doi.org/10.1038/nature15818 (2015).
Nasimuzzaman, M. et al. Production and purification of high-titer foamy virus vector for the treatment of leukocyte adhesion deficiency. Mol. Therapy. Methods Clin. Dev. 3, 16004; https://doi.org/10.1038/mtm.2016.4 (2016).
Sweeney, N. P., Meng, J., Patterson, H., Morgan, J. E. & McClure, M. Delivery of large transgene cassettes by foamy virus vector. Sci. Rep. 7, 8085; https://doi.org/10.1038/s41598-017-08312-3 (2017).
Lehmann-Che, J. et al. Centrosomal latency of incoming foamy viruses in resting cells. PLoS Pathogens 3, e74; https://doi.org/10.1371/journal.ppat.0030074 (2007).
Nowrouzi, A. et al. Genome-wide mapping of foamy virus vector integrations into a human cell line. J. General Virol. 87, 1339–1347; https://doi.org/10.1099/vir.0.81554-0 (2006).
Beard, B. C. et al. Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus. Human Gene Therapy 18, 423–434; https://doi.org/10.1089/hum.2007.011 (2007).
Hendrie, P. C., Huo, Y., Stolitenko, R. B. & Russell, D. W. A rapid and quantitative assay for measuring neighboring gene activation by vector proviruses. Mol. Therapy: J. Am. Soc. Gene Therapy 16, 534–540; https://doi.org/10.1038/sj.mt.6300398 (2008).
Lindemann, D. et al. A Particle-Associated Glycoprotein Signal Peptide Essential for Virus Maturation and Infectivity. J. Virol. 75, 5762–5771; https://doi.org/10.1128/JVI.75.13.5762-5771.2001 (2001).
Ho, Y.-P., Schnabel, V., Swiersy, A., Stirnnagel, K. & Lindemann, D. A small-molecule-controlled system for efficient pseudotyping of prototype foamy virus vectors. Mol. Therapy: J. Am. Soc. Gene Therapy 20, 1167–1176; https://doi.org/10.1038/mt.2012.61 (2012).
Elsner, C. & Bohne, J. The retroviral vector family: something for everyone. Virus Genes 53, 714–722; https://doi.org/10.1007/s11262-017-1489-0 (2017).
Mitchell, R. S. et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2, E234; https://doi.org/10.1371/journal.pbio.0020234 (2004).
Howe, S. J. et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118, 3143–3150; https://doi.org/10.1172/JCI35798 (2008).
Hacein-Bey-Abina, S. et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118, 3132–3142; https://doi.org/10.1172/JCI35700 (2008).
Stein, S. et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 16, 198–204; https://doi.org/10.1038/nm.2088 (2010).
Hacein-Bey-Abina, S. et al. A modified γ-retrovirus vector for X-linked severe combined immunodeficiency. N. E. J. Med. 371, 1407–1417; https://doi.org/10.1056/NEJMoa1404588 (2014).
Zychlinski, D. et al. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol. Therapy: J. Am. Soc. Gene Therapy 16, 718–725; https://doi.org/10.1038/mt.2008.5 (2008).
Maetzig, T., Galla, M., Baum, C. & Schambach, A. Gammaretroviral vectors: biology, technology and application. Viruses 3, 677–713; https://doi.org/10.3390/v3060677 (2011).
Sinn, P. L., Sauter, S. L. & McCray, P. B. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production. Gene Therapy 12, 1089–1098; https://doi.org/10.1038/sj.gt.3302570 (2005).
Meng, J. et al. Autologous skeletal muscle derived cells expressing a novel functional dystrophin provide a potential therapy for Duchenne Muscular Dystrophy. Sci. Rep. 6, 19750; https://doi.org/10.1038/srep19750 (2016).
Kumar, M., Keller, B., Makalou, N. & Sutton, R. E. Systematic determination of the packaging limit of lentiviral vectors. Human Gene Therapy 12, 1893–1905; https://doi.org/10.1089/104303401753153947 (2001).
Schröder, A. R. W. et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110, 521–529; https://doi.org/10.1016/s0092-8674(02)00864-4 (2002).
Rothe, M., Modlich, U. & Schambach, A. Biosafety challenges for use of lentiviral vectors in gene therapy. Current Gene Therapy 13, 453–468; https://doi.org/10.2174/15665232113136660006 (2013).
Naldini, L. Ex vivo gene transfer and correction for cell-based therapies. Nat. Rev. Genetics 12, 301–315; https://doi.org/10.1038/nrg2985 (2011).
Staal, F. J. T., Aiuti, A. & Cavazzana, M. Autologous Stem-Cell-Based Gene Therapy for Inherited Disorders: State of the Art and Perspectives. Front. Pediatrics 7, 443; https://doi.org/10.3389/fped.2019.00443 (2019).
Ferrari, G., Thrasher, A. J. & Aiuti, A. Gene therapy using haematopoietic stem and progenitor cells. Nature reviews. Genetics 22, 216–234; https://doi.org/10.1038/s41576-020-00298-5 (2021).
Cronin, J., Zhang, X.-Y. & Reiser, J. Altering the tropism of lentiviral vectors through pseudotyping. Curr. Gene Therapy 5, 387–398; https://doi.org/10.2174/1566523054546224 (2005).
Heinkelein, M. et al. Improved primate foamy virus vectors and packaging constructs. J. Virol. 76, 3774–3783; https://doi.org/10.1128/jvi.76.8.3774-3783.2002 (2002).
Stirnnagel, K. et al. Analysis of prototype foamy virus particle-host cell interaction with autofluorescent retroviral particles. Retrovirology 7, 45; https://doi.org/10.1186/1742-4690-7-45 (2010).
Luczak, M. W. & Zhitkovich, A. Monoubiquitinated γ-H2AX: Abundant product and specific biomarker for non-apoptotic DNA double-strand breaks. Toxicol. Appl. Pharmacol. 355, 238–246; https://doi.org/10.1016/j.taap.2018.07.007 (2018).
Modlich, U. et al. Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16. Leukemia 22, 1519–1528; https://doi.org/10.1038/leu.2008.118 (2008).
Han, J. et al. β-Globin Lentiviral Vectors Have Reduced Titers due to Incomplete Vector RNA Genomes and Lowered Virion Production. Stem Cell Rep. 16, 198–211; https://doi.org/10.1016/j.stemcr.2020.10.007 (2021).
Sweeney, N. P. & Vink, C. A. The impact of lentiviral vector genome size and producer cell genomic to gag-pol mRNA ratios on packaging efficiency and titre. Mol. Therapy. Methods Clin. Dev. 21, 574–584; https://doi.org/10.1016/j.omtm.2021.04.007 (2021).
Bodem, J. Regulation of foamy viral transcription and RNA export. Adv. Virus Res. 81, 1–31; https://doi.org/10.1016/B978-0-12-385885-6.00006-7 (2011).
Zamborlini, A., Renault, N., Saïb, A. & Delelis, O. Early reverse transcription is essential for productive foamy virus infection. PloS One 5, e11023; https://doi.org/10.1371/journal.pone.0011023 (2010).
Roy, J. et al. Feline foamy virus genome and replication strategy. J. Virol. 77, 11324–11331; https://doi.org/10.1128/jvi.77.21.11324-11331.2003 (2003).
Gobet, C. & Naef, F. Ribosome profiling and dynamic regulation of translation in mammals. Curr. Op. Genetics Dev. 43, 120–127; https://doi.org/10.1016/j.gde.2017.03.005 (2017).
Guo, J., Lian, X., Zhong, J., Wang, T. & Zhang, G. Length-dependent translation initiation benefits the functional proteome of human cells. Mol. Biosyst. 11, 370–378; https://doi.org/10.1039/c4mb00462k (2015).
Castillo-Davis, C. I., Mekhedov, S. L., Hartl, D. L., Koonin, E. V. & Kondrashov, F. A. Selection for short introns in highly expressed genes. Nat. Gene. 31, 415–418; https://doi.org/10.1038/ng940 (2002).
Ross, J. mRNA stability in mammalian cells. Microbiol. Rev. 59, 423–450; https://doi.org/10.1128/mr.59.3.423-450.1995 (1995).
Forrest, M. E. et al. Codon and amino acid content are associated with mRNA stability in mammalian cells. PloS one 15, e0228730; https://doi.org/10.1371/journal.pone.0228730 (2020).
Schambach, A. et al. Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol. Therapy: J. Am. Soc. Gene Therapy 13, 391–400; https://doi.org/10.1016/j.ymthe.2005.08.012 (2006).
Schambach, A. et al. Lentiviral vectors pseudotyped with murine ecotropic envelope: increased biosafety and convenience in preclinical research. Exp. Hematol. 34, 588–592; https://doi.org/10.1016/j.exphem.2006.02.005 (2006).
Barlow, C. et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 86, 159–171; https://doi.org/10.1016/s0092-8674(00)80086-0 (1996).
Khan, M. & Gasser, S. Generating Primary Fibroblast Cultures from Mouse Ear and Tail Tissues. J. Visual. Exp.: JoVE; https://doi.org/10.3791/53565 (2016).
Dull, T. et al. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463–8471; https://doi.org/10.1128/JVI.72.11.8463-8471.1998 (1998).
Yee, J. K. et al. A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc. Natl. Acad. Sci. US A 91, 9564–9568; https://doi.org/10.1073/pnas.91.20.9564 (1994).
Müllers, E. et al. Novel functions of prototype foamy virus Gag glycine- arginine-rich boxes in reverse transcription and particle morphogenesis. J. Virol. 85, 1452–1463; https://doi.org/10.1128/JVI.01731-10 (2011).
Sweeney, N. P. et al. Rapid and efficient stable gene transfer to mesenchymal stromal cells using a modified foamy virus vector. Mol. Therapy: J. Am. Soc. Gene Therapy 24, 1227–1236; https://doi.org/10.1038/mt.2016.91 (2016).
Acknowledgements
We thank Dirk Lindemann (TU Dresden) for discussing our paper and providing plasmids of the foamy viral vector system. We thank Axel Schambach (Hannover Medical School) for providing the gammaretroviral and lentiviral plasmid. UM received funding from the Germany Research Foundation (MO 860/7-1). JR was supported by the SNSF Lead agency program (SNF/310030E_188990), Clinical Research Priority Program (CRPP) ImmuGene, as well as University Research Priority Program of the University of Zurich (URPP) ITINERARE—Innovative Therapies in Rare Diseases of the University of Zurich.
Funding
Open Access funding enabled and organized by Projekt DEAL.
Author information
Authors and Affiliations
Contributions
T.H. designed and generated vectors, produced and titrated viral vector supernatants, performed qPCR and Western Blot experiments, analyzed and visualized the data and wrote the manuscript. N.B. generated vectors, produced and titrated viral vector supernatants, analyzed the data. F.S. generated the vectors, produced and titrated viral vector supernatants, quantified the RNA in viral particles and analyzed data. S.P. quantified the amount of total particles in viral supernatants. J.R. designed the study, discussed the manuscript. R.S. provided analytics for Atm-deficiency and discussed the manuscript. U.M. designed the study, wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Hirch, T., Brander, N., Schenk, F. et al. Expression of a large coding sequence: Gene therapy vectors for Ataxia Telangiectasia. Sci Rep 13, 19386 (2023). https://doi.org/10.1038/s41598-023-46332-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-023-46332-4
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.